PUBLICATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Publications
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
No.75
Cell metab.,
“MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity” (Cell Metab., DOI: 10.1016/j.cmet.2022.10.007., 2022)
VIEW ARTICLE 
No.74
Cell Death & Disease.,
“Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH” (Cell Death & Disease., DOI: 10.1038/s41419-022-05452-x., 2022)
VIEW ARTICLE
No.74
bioRxiv.,
“Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG)” (bioRxiv., DOI: https://doi.org/10.1101/2022.11.17.516628, 2022)
VIEW ARTICLE
No.72
J Clin Exp Hepatol.,
“Hepatoprotective effects of Aureobasidium pullulans derived β 1,3-1,6 glucans in a murine model of non-alcoholic steatohepatitis - Journal of Clinical and Experimental Hepatology” (J Clin Exp Hepatol., DOI:https://doi.org/10.1016/j.jceh.2022.06.008., 2022)
VIEW ARTICLE
No.71
Cell metab.,
“Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia” (Cell Metab. DOI: 10.1016/j.cmet.2022.05.004., 2022)
VIEW ARTICLE
No.70
PLoS One.,
“A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE
No.69
PLoS One.,
“Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model”(PLoS One., DOI: 10.1371/journal.pone.0261310., 2022)
VIEW ARTICLE
No.68
Cells.,
“Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non Alcoholic Steatohepatitis” (Cells., DOI: 10.3390/cells11040720., 2022)
VIEW ARTICLE
No.67
PLoS One.,
“Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosisbut not NASH progression” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE
No.66
Mol Metab.,
“Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function” (Mol Metab., doi: 10.1016/j.molmet.2022.101487., 2022)
VIEW ARTICLE